Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cosela Generic Name & Formulations
Legal Class
Rx
General Description
Trilaciclib 300mg; lyophilized cake for IV infusion after reconstitution and dilution; preservative-free; contains mannitol.
Pharmacological Class
Kinase inhibitor.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Cosela Indications
Indications
To decrease the incidence of chemotherapy-induced myelosuppression when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Cosela Dosage and Administration
Adult
Give by IV infusion over 30mins within 4hrs prior to initiating chemotherapy on each day chemotherapy is administered. 240mg/m2 per dose. Dosing interval on sequential days should not exceed 28hrs. If Cosela is discontinued, wait 96hrs from the last dose of Cosela before resuming chemotherapy only. Dose modification for adverse reactions: see full labeling.
Children
Not established.
Cosela Contraindications
Not Applicable
Cosela Boxed Warnings
Not Applicable
Cosela Warnings/Precautions
Warnings/Precautions
Monitor for inj-site reactions (eg, pain, erythema), including phlebitis, thrombophlebitis; permanently discontinue if Grade 3 or 4 reactions occur. Monitor for hypersensitivity reactions (eg, edema, urticaria, pruritus, anaphylactic reactions); withhold therapy if Grade 2 reactions occur until recovery to Grade ≤1; permanently discontinue if Grade 3 or 4 reactions occur. Monitor for interstitial lung disease (ILD)/pneumonitis (eg, cough, dyspnea, hypoxia); permanently discontinue if Grade 3 or 4, or recurrent Grade 2 occurs. Moderate or severe hepatic impairment: not recommended. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraceptive during and for ≥3 weeks after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥3 weeks after the last dose).
Cosela Pharmacokinetics
See Literature
Cosela Interactions
Interactions
May potentiate certain OCT2, MATE1, MATE-2K substrates (eg, dofetilide, dalfampridine, cisplatin). Increased risk of serious ventricular arrhythmias associated with QT interval prolongation (including torsade de pointes) with concomitant dofetilide. Increased risk of seizures with concomitant dalfampridine. Monitor closely for dose-related nephrotoxicity with concomitant cisplatin.
Cosela Adverse Reactions
Adverse Reactions
Fatigue, hypocalcemia, hypokalemia, hypophosphatemia, increased AST, headache, pneumonia; respiratory failure, hemorrhage, thrombosis.
Cosela Clinical Trials
See Literature
Cosela Note
Not Applicable
Cosela Patient Counseling
See Literature
Images
